Bicara Change In Cash from 2010 to 2026

BCAX Stock   14.21  0.15  1.07%   
Bicara Therapeutics Change In Cash yearly trend continues to be fairly stable with very little volatility. Change In Cash will likely drop to about 177.8 M in 2026. During the period from 2010 to 2026, Bicara Therapeutics Change In Cash regression line of annual values had significance of  0 and arithmetic mean of  56,123,038. View All Fundamentals
 
Change In Cash  
First Reported
2010-12-31
Previous Quarter
298.2 M
Current Value
177.8 M
Quarterly Volatility
107.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Bicara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bicara Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 225.8 K, Net Interest Income of 17.6 M or Interest Income of 17.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.82. Bicara financial statements analysis is a perfect complement when working with Bicara Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Bicara Stock
Check out the analysis of Bicara Therapeutics Correlation against competitors.
The evolution of Change In Cash for Bicara Therapeutics Common provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Bicara Therapeutics compares to historical norms and industry peers.

Latest Bicara Therapeutics' Change In Cash Growth Pattern

Below is the plot of the Change In Cash of Bicara Therapeutics Common over the last few years. It is Bicara Therapeutics' Change In Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bicara Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Change In Cash10 Years Trend
Slightly volatile
   Change In Cash   
       Timeline  

Bicara Change In Cash Regression Statistics

Arithmetic Mean56,123,038
Coefficient Of Variation191.80
Mean Deviation86,711,588
Median(573,000)
Standard Deviation107,646,759
Sample Variance11587.8T
Range298.7M
R-Value0.71
Mean Square Error6055.6T
R-Squared0.51
Significance0
Slope15,224,690
Total Sum of Squares185405.2T

Bicara Change In Cash History

2026177.8 M
2025298.2 M
2024259.3 M
2023226.3 M

About Bicara Therapeutics Financial Statements

Bicara Therapeutics investors use historical fundamental indicators, such as Bicara Therapeutics' Change In Cash, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bicara Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Change In Cash298.2 M177.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Bicara Stock Analysis

When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.